Abstract No. 570 Toxicity and Survival Outcomes of Yttrium-90 Radioembolization Treatment in Patients with Metabolic Dysfunction–Associated Steatohepatitis-Derived Hepatocellular Carcinoma
The global prevalence ofmetabolic dysfunction-associated steatohepatitis (MASH) is increasing, leading to a subsequent rise in MASH-derived hepatocellular carcinoma (HCC). This study explores the toxicity and survival outcomes of yttrium-90 (Y-90) trans-arterial radioembolization (TARE) treatment in patients with MASH-associated HCC.
vigna
0
0
The global prevalence ofmetabolic dysfunction-associated steatohepatitis (MASH) is increasing, leading to a subsequent rise in MASH-derived hepatocellular carcinoma (HCC). This study explores the toxicity and survival outcomes of yttrium-90 (Y-90) trans-arterial radioembolization (TARE) treatment in patients with MASH-associated HCC.
